| Bioactivity | Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity[1][2]. | ||||||||||||
| Invitro | Alofanib inhibits phosphorylation of FRS2α with IC50s of 7 and 9 nM in hFOB and SUM 52PE cells expressing different FGFR2 isoforms[1]. Alofanib (0.2-0.8 μM, 6 hours) inhibits FGF-mediated proliferation in a panel of four cell lines representing several tumour types (triple-negative breast cancer, melanoma, and ovarian cancer) with GI50s of 16-370 nM[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | Alofanib | ||||||||||||
| CAS | 1612888-66-0 | ||||||||||||
| Formula | C19H15N3O6S | ||||||||||||
| Molar Mass | 413.40 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Alofanib
CAS: 1612888-66-0 F: C19H15N3O6S W: 413.40
Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Antican
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.